ApoptoSENS
Biotechnology company developing CAR-NK cell therapies to target and eliminate senescent cells implicated in aging and age-related diseases.
Website
https://www.apoptosens.comLocation
United States
Founded
2022
Investors
1
Categories
biotech, longevity, cell-therapy, senescence, car-nk
Notes
ApoptoSENS is developing CAR-NK (chimeric antigen receptor natural killer) cell therapies aimed at targeting and eliminating senescent cells. Cellular senescence - the accumulation of damaged, non-dividing cells that secrete inflammatory factors - has been implicated in aging and various age-related diseases.
By selectively destroying senescent cells, ApoptoSENS aims to reduce the inflammatory burden associated with aging and potentially treat or prevent age-related conditions. The company received funding from VitaDAO, a decentralized organization supporting longevity research.
Team
- Research team focused on senolytic cell therapies
Additional Research Findings
- Funded $253,000 by VitaDAO in September 2022
- CAR-NK cell therapies for senescent cell elimination
- Senolytic approach to aging and age-related diseases
- Targeting senescence-associated secretory phenotype (SASP)
- Part of the growing longevity/anti-aging biotech sector
- Natural killer cell-based therapeutic platform
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| VitaDAO | Decentralized (Global) | dao | seed | 7 |